Moleculin Biotech is trading 6% up at $0.76 after investors reacted to encouraging interim Phase 3 Annamycin data presented through the H.C. Wainwright conference on September 11, 2026.
- The update highlighted higher remission rates in relapsed or refractory AML without observed cardiotoxicity.
- The MIRACLE trial remains ongoing.
- Additional data is expected later in 2026 or early 2027.